EquityZen Growth Technology Fund LLC - Series 1931
Raised
$306K
Investors
11
Min Invest
$10,120
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1931 is a Delaware pooled investment fund vehicle filed by EquityZen Advisors LLC on 2024-09-25. The fund raised $306K from 11 investors under Rule 506(b) and 3(c)(1) exemptions, with a $10K minimum investment. It is part of the EquityZen platform, which operates 1889+ related entities focused on pre-IPO secondary market access.
This pre-IPO fund follows the standard EquityZen platform structure: 506(b)/3(c)(1) exemptions with retail-accessible minimums ($10K). The $27.8K average check size and 11-investor count align with typical series-level SPVs in the EquityZen ecosystem, which aggregates smaller investors for access to private company shares.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.